Nick la Thangue

Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland.

Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants.

Pfizer Europe International Ltd. is an Irish company.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

Part of Pfizer Inc., Pfizer Japan, Inc. is a research and Japanese development pharmaceutical company founded in 1953. The company is based in Tokyo, Japan. The company's focus is on breakthroughs that greatly change patients' lives, contributing to the improvement of patients' health and life expectancy.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom.

NightBalance BV develops and markets sensor-devices for the treatment of sleep apnea. It offers sleep position trainer, a small and light aid which can be worn around the chest with an ergonomic band. The firm's a sleep position sensor which gradually and comfortably trains patients using vibrations to not sleep on their back. The company was founded by Eline van Beest and Thijs van Oorschot in 2009 and is headquartered in The Hague, the Netherlands.

Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands.

Part of Portage Biotech, Inc., Portage Pharma Ltd. develops pharmaceutical products. The There is no available country named vg company was founded by Declan Doogan, Gregory H. Bailey. Bruce H. Littman has been the CEO of the company since 2013. Portage Pharma was acquired by Portage Biotech, Inc. on June 04, 2013 for $34.84 million.

The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK.

Mediqventures Ltd. provides financing services for life science technologies. The private company is based in Douglas, UK. The British company was founded by Gregory H. Bailey.

Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT.

Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

BYOMass, Inc. provides investment holding services. The company is headquartered in Sudbury, MA.

Causeway Therapeutics Ltd. operates as a biotechnology company. It develops drugs for the treatment for patients. The company was founded by Derek S. Gilchrist and Neal L. Millar and is headquartered in Glasgow, the United States.

Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom.